| Followers | 10 |
| Posts | 1467 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Friday, January 30, 2015 10:24:45 AM
Those who are just players and calculate the odds like this.
______________________________________________
In recent months NanoViricide has put their science on the line. BASi has preformed preliminary FluCide Tox testing.
USAMRIID is conducting EbolaCide efficacy testing.
Before Q2 is over Bears and Bulls will have these provisional 3rd party results to determine their investment position.
__________________________________________________________
Those of us who are here for the science also like this as the ball is bouncing and gravity (time) will settle the question soon.
AS soon as BASi gives it clearance it will be a go outside our borders. Preceding this the Army will be blessing NNVC's use in Africa. I am glad the Ebola seems to have slowed down, but saving the lives of those who are in the ending cohort is wonderful.
______________________________________________
In recent months NanoViricide has put their science on the line. BASi has preformed preliminary FluCide Tox testing.
USAMRIID is conducting EbolaCide efficacy testing.
Before Q2 is over Bears and Bulls will have these provisional 3rd party results to determine their investment position.
__________________________________________________________
Those of us who are here for the science also like this as the ball is bouncing and gravity (time) will settle the question soon.
AS soon as BASi gives it clearance it will be a go outside our borders. Preceding this the Army will be blessing NNVC's use in Africa. I am glad the Ebola seems to have slowed down, but saving the lives of those who are in the ending cohort is wonderful.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
